Genetic Factors Influence Heart Remodeling and Hypertrophic Cardiomyopathy

A recent groundbreaking study by the LMS's computational cardiac imaging group, led by Professor Declan O'Regan, has shed new light on the genetic determinants of heart remodeling and hypertrophic cardiomyopathy, a disease that can lead to sudden death. The study, published in Circulation: Genomics and Precision Medicine, conducted a three-dimensional genome-wide analysis (3D GWAS) of the heart, revealing 42 new genetic locations that influence the left ventricle's remodelling and hypertrophy, 18 of which were not identifiable through traditional GWAS techniques. This research has significant implications for early identification of individuals at risk for hypertrophic heart disease and may inform interventions to protect long-term cardiac health.

Key Takeaways:

• The study found 42 new genetic locations (loci) that influence remodelling and hypertrophy of the left ventricle, out of which 18 could not be identified using traditional GWAS techniques.
• These genetic factors can affect how an individual's heart adapts to changing demands, making them more susceptible to hypertrophic heart disease later in life.
• The study highlighted the importance of considering structural variations in the heart when investigating genetic associations, demonstrated through the use of three-dimensional MRI images.
• The research may lead to the development of early interventions to protect long-term cardiac health and identify individuals at risk for hypertrophic cardiomyopathy.
• The study also implicated genes linked to excessive thickening of the heart muscle, a hallmark of hypertrophic cardiomyopathy, which can lead to sudden death.

Statistics:

• 42 new genetic locations (loci) were identified as influencing remodelling and hypertrophy of the left ventricle.
• 18 of these genetic locations could not be identified using traditional GWAS techniques.
• The study used data from over 40,000 people.
• The research was funded by the British Heart Foundation, the Medical Research Council, the Engineering and Physical Sciences Research Council, the Sir Jules Thorn Charitable Trust, the NIHR Imperial College Biomedical Research Centre, and the NIHR University College London Biomedical Research Centre.

Sources:

• Circulation: Genomics and Precision Medicine
• British Heart Foundation
• Medical Research Council
• Engineering and Physical Sciences Research Council
• Sir Jules Thorn Charitable Trust
• NIHR Imperial College Biomedical Research Centre
• NIHR University College London Biomedical Research Centre